TranS1
Medical Devices & Tech
411 Landmark Drive
Wilmington, NC 28412 USA
phone: 910-332-1700
fax: 910-332-1701
Symbol Private
Founded 0
Employees
www.trans1inc.com
Research Sector Medical Devices & Tech
Summary Description
Minimally invasive fusion system for the treatment of lower back pain
Management
Rick Randall, President & CEO; Michael Luetkemeyer, CFO; Rick Simmons, Vice President of Marketing and Sales; Robert Assell, Vice President of Product Development; Robert Sheridan, Vice President of Regulatory and Clinical Affairs
Keywords
spine, orthopedics, minimally invasive, advamed, back surgery, j2008b

Comment | Printable Version | Dec. 30, 2007
If you work for TranS1 and want to update this profile, click here

Description
TranS1, Inc. is an early stage medical device company dedicated to advancing the minimally invasive technique for spine disorders.
Products / Services
TranS1's percutaneous access and fusion system enables lumbar fusion to be performed with complete preservation of the annulus and all paraspinal soft tissue structures. AxiaLIF (Axial Lumbar Interbody Fusion) offers a reproducible pre-sacral access route to the L5-S1 vertebral bodies and can be performed through an outpatient surgical procedure, allowing for a rapid return to normal activities.
Technology / Differentiation
TranS1 uses the Cragg Spinal Access Approach, which spares injury to the disc annulus and the paraspinal muscles and ligaments supporting the spine. This minimally invasive approach allows patients to be discharged from the hospital the day after surgery, and return to work in 15 days on average. This is a dramatic reduction in hospital stay, which can otherwise run three to four nights, followed by a one-to-two month recovery period before returning to work.
Market / Customers
Lower back disorders affect 15-20% of the U.S. population and result in approximately 6.5 million doctors' visits each year. These visits are often caused by degenerative disc disease, a painful condition characterized by chronic lower back pain. The specific etiology of degenerative disc disease is unknown. It is believed to be caused by a number of factors, including mechanical, chemical, and age-related changes, autoimmune response, and hereditary factors.
Strategy
In September 2006, TranS1 signed an exclusive agreement with ApaTech for distribution of its AxiaLIF system in the U.K. and Ireland. TranS1 is also developing two mobility platforms - a disc replacement and a prosthetic disc nucleus; both are delivered using the percutaneous, trans-sacral approach.
Funding
In July 2007, Trans1 filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. Lehman Brothers Inc. and Piper Jaffray & Co. will act as joint book-running managers for the offering with Cowen and Company, LLC and Leerink Swann & Co., Inc. acting as co-managers.
Status
As of January 30, 2007 more than 1,000 patients had used AxiaLIF.


2008-10-11-2411